About Aiforia
Aiforia Technologies is a digital pathology company that transforms pathology image analysis through artificial intelligence, enabling better care for each patient. The company equips pathologists and scientists in clinical, pre-clinical, and academic laboratories with powerful deep learning AI and cloud-based technology designed to increase the speed, accuracy, and consistency of analyzing large and complex medical images, especially in pathology. Aiforia's comprehensive portfolio includes CE-IVD marked Clinical Suites for breast, lung, prostate, gastric, and colorectal cancers, offering fully automated case-centric workflows that enhance diagnostic accuracy and productivity. These solutions provide AI-driven image analysis, standardized scoring, and automated reporting to achieve objective, quantitative, and explainable results. The company's research solutions offer study-centric workflows and pathology image analysis applications that cater to all research areas, empowering pathologists and scientists to make discoveries while automating repetitive tasks within GLP frameworks. At the core of Aiforia's offering is Aiforia® Create, a versatile cloud-based tool for developing deep learning AI models for image analysis in digital pathology. Its collaborative working environment allows multiple users to work together in real time from anywhere in the world, with an intuitive user interface that enables fast adoption even without prior AI experience. Aiforia's solutions integrate with existing laboratory infrastructure and are deployed in clinical settings worldwide, serving pathology laboratories, research institutions, pharmaceutical companies, and veterinary diagnostic labs.
Mission & Story
Mission
Aiforia's mission is to transform pathology image analysis with AI, enabling better care for each patient.
Clinical Focus
Medical conditions and clinical areas addressed by Aiforia.
Who It Serves
Milestones & Awards
Recent Milestones
Announced next generation CE-IVD marked Prostate Cancer Biopsy AI solution. Expanded clinical suite portfolio across multiple cancer types.
Key Partnerships
Social & Media
Latest Updates
Aiforia expands its presence in Spain through a new clinical account
1mo ago
Fimlab expands utilization of Aiforia's clinical AI solutions
2mo ago
Aiforia closes a deal with a private diagnostic laboratory in Italy
2mo ago
Aiforia has been selected as an AI partner for the PROSTIA project - expands to five new hospitals in Paris
3mo ago
Aiforia announces the next generation of its CE-IVD marked Prostate Cancer Biopsy AI solution
4mo ago
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.